Styliani Mantziari1, Anna Dayer1,2, Céline Duvoisin1, Nicolas Demartines1, Pierre Allemann1, Jean-Marie Calmes1, Lucie Favre3, Pierre Fournier1, Michel Suter4,5. 1. Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland. 2. Department of Surgery, Riviera-Chablais Hospital, Aigle-Monthey, Switzerland. 3. Department of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland. 4. Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland. michelsuter@netplus.ch. 5. Department of Surgery, Riviera-Chablais Hospital, Aigle-Monthey, Switzerland. michelsuter@netplus.ch.
Abstract
BACKGROUND: Conflicting data have been published for bariatric surgery in older patients, with no long-term large-scale studies available. Our aim was to provide long-term (> 10 years) results on weight loss, metabolic outcomes, and quality of life in a large homogenous series of Roux-en-Y gastric bypass (RYGB) patients, according to age at baseline. PATIENTS AND METHODS: All consecutive patients who underwent primary RYGB between 1999 and 2007, and therefore eligible for 10-year follow-up, were retrospectively analyzed. According to their age at baseline, they were divided into three groups: A (< 40 years), B (40-54 years), and C (≥ 55 years). Categorical variables were compared with the χ2 test and continuous variables with ANOVA. RESULTS: Our series consisted of 820 patients, with a 10-year follow-up of 80.6%. Although group C (11% of all patients) had significantly more comorbidities at baseline, there was no difference in postoperative morbidity and mortality between groups. Weight loss was significantly less for group C patients up to the 7th postoperative year, but no difference remained thereafter. 10-year %total weight loss was 32.2, 32.9, and 32.3 respectively in groups A, B, and C. After 10 years, glycemic control and lipid profile improved similarly, rates of partial or complete remission of diabetes and hypertension were identical, and quality of life presented a significant improvement for all patients with no inter-group difference. CONCLUSION: Our results suggest similar short- and long-term outcomes after RYGB for patients ≥ 55 years compared to younger ones; the relative benefit might even be higher for older patients, given their increased comorbidity at baseline.
BACKGROUND: Conflicting data have been published for bariatric surgery in older patients, with no long-term large-scale studies available. Our aim was to provide long-term (> 10 years) results on weight loss, metabolic outcomes, and quality of life in a large homogenous series of Roux-en-Y gastric bypass (RYGB) patients, according to age at baseline. PATIENTS AND METHODS: All consecutive patients who underwent primary RYGB between 1999 and 2007, and therefore eligible for 10-year follow-up, were retrospectively analyzed. According to their age at baseline, they were divided into three groups: A (< 40 years), B (40-54 years), and C (≥ 55 years). Categorical variables were compared with the χ2 test and continuous variables with ANOVA. RESULTS: Our series consisted of 820 patients, with a 10-year follow-up of 80.6%. Although group C (11% of all patients) had significantly more comorbidities at baseline, there was no difference in postoperative morbidity and mortality between groups. Weight loss was significantly less for group C patients up to the 7th postoperative year, but no difference remained thereafter. 10-year %total weight loss was 32.2, 32.9, and 32.3 respectively in groups A, B, and C. After 10 years, glycemic control and lipid profile improved similarly, rates of partial or complete remission of diabetes and hypertension were identical, and quality of life presented a significant improvement for all patients with no inter-group difference. CONCLUSION: Our results suggest similar short- and long-term outcomes after RYGB for patients ≥ 55 years compared to younger ones; the relative benefit might even be higher for older patients, given their increased comorbidity at baseline.
Authors: Robert B Dorman; Anasooya A Abraham; Waddah B Al-Refaie; Helen M Parsons; Sayeed Ikramuddin; Elizabeth B Habermann Journal: J Gastrointest Surg Date: 2011-10-27 Impact factor: 3.452
Authors: Zubaidah Nor Hanipah; Suriya Punchai; Linden A Karas; Samuel Szomstein; Rahul J Rosenthal; Stacy A Brethauer; Ali Aminian; Philip R Schauer Journal: Obes Surg Date: 2018-06 Impact factor: 4.129
Authors: Ted D Adams; Richard E Gress; Sherman C Smith; R Chad Halverson; Steven C Simper; Wayne D Rosamond; Michael J Lamonte; Antoinette M Stroup; Steven C Hunt Journal: N Engl J Med Date: 2007-08-23 Impact factor: 91.245
Authors: Rena C Moon; Flavio Kreimer; Andre F Teixeira; Josemberg M Campos; Alvaro Ferraz; Muhammad A Jawad Journal: Obes Surg Date: 2016-04 Impact factor: 4.129
Authors: Céline Duvoisin; Lucie Favre; Pierre Allemann; Pierre Fournier; Nicolas Demartines; Michel Suter Journal: Ann Surg Date: 2018-12 Impact factor: 12.969
Authors: Daniel Gero; Lucie Favre; Pierre Allemann; Pierre Fournier; Nicolas Demartines; Michel Suter Journal: Obes Surg Date: 2018-03 Impact factor: 4.129
Authors: Anne-Sophie van Rijswijk; Nienke van Olst; Winnie Schats; Donald L van der Peet; Arnold W van de Laar Journal: Obes Surg Date: 2021-05-17 Impact factor: 4.129
Authors: Rishi Singhal; Islam Omar; Brijesh Madhok; Yashasvi Rajeev; Yitka Graham; Abd A Tahrani; Christian Ludwig; Tom Wiggins; Kamal Mahawar Journal: Obes Surg Date: 2022-05-05 Impact factor: 3.479
Authors: Piotr Major; Tomasz Stefura; Błażej Dziurowicz; Joanna Radwan; Michał Wysocki; Piotr Małczak; Michał Pędziwiatr Journal: Obes Surg Date: 2020-06-13 Impact factor: 4.129